FUSN

Fusion Pharmaceuticals Announces Preliminary Safety and Dosimetry Results from its Single-Dose Portion of the Phase 1 Study of FPI-1434

Fusion Pharmaceuticals Appoints Isabelle Dussault, Ph.D. as Senior Vice President, Research

Fusion Pharmaceuticals Enters into Agreement to Build Radiopharmaceutical Manufacturing Facility

Fusion Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

Fusion Pharmaceuticals Announces First Quarter 2021 Financial Results and Business Update

Fusion Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate Fusion's Targeted Alpha Therapy (TAT) in Combination with Merck's KEYTRUDA® (pembrolizumab) in Patients With Solid Tumors Expressing IGF-1R

Fusion Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference